Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AEB 071; NVP-AEB071; Sotrastaurin acetate

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Ohio State University
  • Developer Novartis
  • Class Piperazines; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action Immunosuppressants; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Uveal melanoma
  • Discontinued Liver transplant rejection; Psoriasis; Renal transplant rejection; Transplant rejection; Ulcerative colitis; Uveitis

Most Recent Events

  • 17 Jul 2019 Phase-I development for Uveal melanoma (Metastatic disease) is still ongoing in USA, UK, France and Netherlands (NCT01430416)
  • 22 May 2019 Novartis completes a phase I trial in Uveal melanoma in USA, UK, France and Netherlands (NCT01430416)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top